Skip to main content

Table 2 Comparison of first-line treatments for uterine versus non-uterine LMS

From: A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments

Treatment Uterine LMS Non-uterine LMS Total LMS
(n = 24), (n = 24), (N = 48),
n (%) n (%) n (%)
Anthracycline-based 7 (29.2) 11 (45.8) 18 (37.5)
Gemcitabine-based 11 (45.8) 10 (41.7) 21 (43.8)
Alkylating agents 1 (4.2) 1 (4.2) 2 (4.2)
Angiogenesis inhibitors 1 (4.2) 1 (4.2) 2 (4.2)
Trabectedin 2 (8.3) 1 (4.2) 3 (6.3)
Other 2 (8.3) 0 (0.0) 2 (4.2)
  1. Abbreviation: LMS leiomyosarcomas.